舒泰神 reported revenue of ¥0.09B for the period ended 2026-06-30, -26.0% year on year. Net income was ¥-0.04B, a -41.8% net margin on a 74.1% gross margin. The largest revenue line is 注射用鼠神经生长因子(苏肽生) at 68% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.09B | -26.0% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥-0.04B | — |
| Net income | ¥-0.04B | — |
| Gross margin | 74.1% | Net margin -41.8% |
| Revenue Q/Q | -1.9% | — |
| Segment | Revenue | Share |
|---|---|---|
| 注射用鼠神经生长因子(苏肽生) | ¥0.06B | 68.5% |
| 其他 | ¥0.01B | 16.1% |
| 聚乙二醇电解质散剂(舒泰清) | ¥0.01B | 15.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.02B | 25.9% |
| R&D | ¥0.03B | 32.1% |
| SG&A | ¥0.07B | 74.1% |
| Tax & other | ¥0.00B | 0.9% |
| Item | Amount |
|---|---|
| Total assets | ¥1.30B |
| Total liabilities | ¥0.51B |
| Shareholders' equity | ¥0.79B |
| Equity / assets | 60.7% |
| Operating cash flow | ¥-0.02B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 99% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
*ST天喻 ・ 理邦仪器 ・ 欣旺达 ・ 行云科技 ・ 森远股份 ・ *ST亿通 ・ *ST易录 ・ 佳讯飞鸿 ・ 日科化学 ・ 电科院 ・ 东方电热 ・ 安利股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies